Shares of Advanced Medical Solutions Group plc (LSE:AMS) rose 3% following the company’s upbeat outlook for the first half of 2025, with revenues expected to reach around £110 million.
The medical tech company projects an adjusted EBITDA in the range of £24.0 million to £24.5 million for the period. While specific analyst consensus for H1 was not available, the firm confirmed that its results are tracking as anticipated and expressed confidence in achieving full-year goals.
Advanced Medical Solutions pointed to solid growth momentum in its core surgical product lines. The integration of recent acquisitions, Peters Surgical and Syntacoll, is reportedly progressing smoothly.
Additionally, the company finalized a restructuring of its Wound Care division by March-end, which has already contributed to margin improvements starting in the second quarter.
The outlook suggests a stronger second half of 2025, with a greater proportion of revenue and EBITDA expected in the latter six months.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply